A PharmaShots Quarterly Analysis
Q2 was one of the most active quarters in recent memory for the pharmaceutical and biotech industry. Big Pharma leaned hard into M&A and licensing to refill pipelines, the FDA cleared a broad slate of new therapies, and AI-native partnerships continued to reshape how drugs get discovered. Below, we break down the quarter…
Shots:
BioLab balances innovation with real-world impact through a dual strategy that combines rapid commercialization of FDA-approved or near-market solutions like Imbed with continued investment in long-term innovations such as cureVision and terraplasma, ensuring both immediate clinical needs and future breakthroughs in wound care are effectively addressed.
BioLab’s growth is driven by sharp strategic discipline, focusing on chronic outpatient…
Shots:
Lilly leads with precision and purpose with 45 deals totaling $21.22B in 2025, focusing on platform-driven, science-led partnerships across oncology, gene therapy, RNA editing, and AI-enabled discovery while building durable innovation engines rather than chasing short-term wins
Strategic dealmaking over sheer volume is evident in partnerships like precision oncology with Scorpion Therapeutics and CNS delivery with Sangamo, structured to…
Shots:
Initial Public Offerings (IPOs) serve as a strategic avenue for private healthcare companies to enhance liquidity, secure capital, and strengthen market presence. Beyond fundraising, going public often paves the way for strategic partnerships and expanded industry influence.
Galderma led the IPO landscape in 2024, raising a staggering $2.54B, followed by BrightSpring Health Services and…
Introducing the third installment of our recently launched Complimentary Exclusive Video Interview. Jonathan Usuka, Chief Business Officer at Sapient, highlighted Sapient’s high throughput proteomics and metabolomics capabilities to generate multi-omics data and the analytical power to transcend the genome to achieve robust biological discoveries in expediting clinical studies.
By leveraging Sapient's real-world data asset, the…

